Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
A 62-year-old man had been treated with combined androgen blockade due to cT2bN1M0 prostate cancer, and his serum prostate-specific antigen (PSA) levels decreased and remained under the level of 0.5 ng/mL during therapy. Approximately 40 months after the initial therapy, difficulty on urination and constipation developed gradually, and serum carcinoembryonic antigen (CEA) and pro-gastrin-releasing peptide (ProGRP) levels were high at this point. He underwent transrectal and transurethral biopsy of the prostate, which revealed adenocarcinoma positive for CEA and chromogranin A. He received palliative pelvic irradiation, and oral estramustine phosphate and etoposide combined therapy. Tumor markers decreased and clinical symptoms improved for several months. The patient died of encephalopathy of unknown etiology approximately 11 months after the relapse.
Kinebuchi
Yoshiaki
Y
Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan. kinebu@hsp.md.shinshu-u.ac.jp
Noguchi
Wataru
W
Irie
Kyoko
K
Nakayama
Tsuyoshi
T
Kato
Haruaki
H
Nishizawa
Osamu
O
D000230:Adenocarcinoma / Q000097:blood* / Q000473:pathology*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology*
D002272:Carcinoembryonic Antigen; D017430:Prostate-Specific Antigen